Secretoneurin Gene Therapy Improves Blood Flow in an Ischemia Model in Type 1 Diabetic Mice by Enhancing Therapeutic Neovascularization

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Schgoer, Wilfried ^a   Theurl, Markus ^a   Albrecht Schgoer, Karin ^a   Jonach, Verena ^a   Koller, Bernhard ^a   Lener, Daniela ^a   Franz, Wolfgang M ^a   Kirchmair, Rudolf ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

SECRETONEURIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTERIOLE; ARTICLE; CAPILLARY; CELL CULTURE; CELL PROLIFERATION; CHEMOTAXIS; CONTROLLED STUDY; DRUG EFFECT; FEMALE; GENE THERAPY; HUMAN; HUMAN CELL; HYPERGLYCEMIA; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; LEG BLOOD FLOW; LEG ISCHEMIA; LIMB PERFUSION; MOUSE; NONHUMAN; STREPTOZOCIN DIABETES; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; CELLS, CULTURED; DIABETES MELLITUS, EXPERIMENTAL; DIABETES MELLITUS, TYPE 1; ENDOTHELIUM, VASCULAR; GENETIC THERAPY; HUMANS; ISCHEMIA; MICE; NEOVASCULARIZATION, PHYSIOLOGIC; NEUROPEPTIDES; REGIONAL BLOOD FLOW; SECRETOGRANIN II; STREPTOZOCIN;

EID: 84884509255     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0074029     Document Type: Article

References (32)

1. Beckman JA, Creager MA, Libby P, (2002) Diabetes and atherosclerosis: epidemiology, pathophysiology, and management. J Am Med Assoc 287: 2570-2581.
2. Waltenberger J, (2001) Impaired collateral vessel development in diabetes: potential cellular mechanisms and therapeutic implications. Cardiovasc Res 49: 554-560.
3. Ahari A, Bergqvist D, Troeng T, Elfstrom J, Hedberg B, et al. (1999) Diabetes mellitus as a risk factor for early outcome after carotid endarterectomy-a population-based study. Eur J Vasc Endovasc 18: 122-126.
4. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, et al. (1998) Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 32: 1866-1873.
5. Kip KE, Faxon DP, Detre KM, Yeh W, Kelsey SF, et al. (1996) Coronary angioplasty in diabetic patients. The National Heart, Lung, and Blood Institute Percutaneous Transluminal Coronary Angioplasty Registry. Circulation 94: 1818-1825.
6. Mathew V, Gersh BJ, Williams BA, Laskey WK, Willerson JT, et al. (2004) Outcomes in patients with diabetes mellitus undergoing percutaneous coronary intervention in the current era: a report from the Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation 109: 476-480.
7. Rivard A, Silver M, Chen D, Kearney M, Magner M, et al. (1999) Rescue of diabetes-related impairment of angiogenesis by intramuscular gene therapy with adeno-VEGF. Am J Pathol 154: 355-363.
8. Belch J, Hiatt WR, Baumgartner I, Driver IV, Nikol S, et al. (2011) Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia. Lancet 377: 1929-1937.
9. Kusumanto YH, van Weel V, Mulder NH, Smit AJ, van den Dungen JJ, et al. (2006) Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. Hum Gene Ther 17: 683-691.
10. Makinen K, Manninen H, Hedman M, Matsi P, Mussalo H, et al. (2002) Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. Mol Ther 6: 127-133.
11. Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, et al. (2003) Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication. Circulation 108: 1933-1938.
12. Rajagopalan S, Trachtenberg J, Mohler E, Olin J, McBride S, et al. (2002) Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. Am J Cardiol 90: 512-516.
13. Sasso FC, Torella D, Carbonara O, Ellison GM, Torella M, et al. (2005) Increased vascular endothelial growth factor expression but impaired vascular endothelial growth factor receptor signaling in the myocardium of type 2 diabetic patients with chronic coronary heart disease. J Am Coll Cardiol 46: 827-834.
14. Brem H, Jacobs T, Vileikyte L, Weinberger S, Gibber M, et al. (2003) Wound-healing protocols for diabetic foot and pressure ulcers. Surg Technol Int 11: 85-92.
15. Kirchmair R, Egger M, Walter DH, Eisterer W, Niederwanger A, et al. (2004) Secretoneurin, an angiogenic neuropeptide, induces postnatal vasculogenesis. Circulation 110: 1121-1127.
16. Kirchmair R, Gander R, Egger M, Hanley A, Silver M, et al. (2004) The neuropeptide secretoneurin acts as a direct angiogenic cytokine in vitro and in vivo. Circulation 109: 777-783.
17. Egger M, Schgoer W, Beer AG, Jeschke J, Leierer J, et al. (2007) Hypoxia up-regulates the angiogenic cytokine secretoneurin via an HIF-1alpha- and basic FGF-dependent pathway in muscle cells. FASEB J 21: 2906-2917.
18. Schgoer W, Theurl M, Jeschke J, Beer AG, Albrecht K, et al. (2009) Gene therapy with the angiogenic cytokine secretoneurin induces therapeutic angiogenesis by a nitric oxide-dependent mechanism. Circ Res 105: 994-1002.
19. Albrecht-Schgoer K, Schgoer W, Holfeld J, Theurl M, Wiedemann D, et al. (2012) The angiogenic factor secretoneurin induces coronary angiogenesis in a model of myocardial infarction by stimulation of vascular endothelial growth factor signaling in endothelial cells. Circulation 126: 2491-2501.
20. Heil M, Ziegelhoeffer T, Wagner S, Fernandez B, Helisch A, et al. (2004) Collateral artery growth (arteriogenesis) after experimental arterial occlusion is impaired in mice lacking CC-chemokine receptor-2. Circ Res 94: 671-677.
21. Baker M, Robinson SD, Lechertier T, Barber PR, Tavora B, et al. (2012) Use of the mouse aortic ring assay to study angiogenesis. Nat Protoc 7: 89-104.
22. Baumgartner I, Pieczek A, Manor O, Blair R, Kearney M, et al. (1998) Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. Circulation 97: 1114-1123.
23. Baumgartner I, Rauh G, Pieczek A, Wuensch D, Magner M, et al. (2000) Lower-extremity edema associated with gene transfer of naked DNA encoding vascular endothelial growth factor. Ann Intern Med 132: 880-884.
24. Roguin A, Avivi A, Nitecki S, Rubinstein I, Levy NS, et al. (2003) Restoration of blood flow by using continuous perimuscular infiltration of plasmid DNA encoding subterranean mole rat Spalax ehrenbergi VEGF. P Natl Acad Sci USA 100: 4644-4648.
25. Roguin A, Nitecki S, Rubinstein I, Nevo E, Avivi A, et al. (2003) Vascular endothelial growth factor (VEGF) fails to improve blood flow and to promote collateralization in a diabetic mouse ischemic hindlimb model. Cardiovasc Diabetol 2: 18.
26. Federman DG, Bravata DM, Kirsner RS, (2004) Peripheral arterial disease. A systemic disease extending beyond the affected extremity. Geriatrics 59: 26, 29-30, 32 passim.
27. Akhtar S, Yousif MH, Chandrasekhar B, Benter IF, (2012) Activation of EGFR/ERBB2 via pathways involving ERK1/2, P38 MAPK, AKT and FOXO enhances recovery of diabetic hearts from ischemia-reperfusion injury. PLoS One 7 (6):: e39066.
28. Dunn LL, Buckle A, Ng MK, (2010) The emerging role of the thioredoxin system in angiogenesis. Arterioscler Thromb Vasc Biol 30 (11):: 2089-2098.
29. Li X, Rong Y, Zhang M, Wang XL, LeMaire SA, et al. (2009) Up-regulation of thioredoxin interacting protein (Txnip) by p38 MAPK and FOXO1 contributes to the impaired thioredoxin activity and increased ROS in glucose-treated endothelial cells. Biochem Biophys Res Commun 381: 660-665.
30. Zippo A, De Robertis A, Bardelli M, Galvagni F, Oliviero S, (2004) Identification of Flk-1 target genes in vasculogenesis: Pim-1 is required for endothelial and mural cell differentiation in vitro. Blood 103 (12):: 4536-44.
31. Katare R, Caporali A, Zentilin L, Avolio E, Sala-Newby G, et al. (2011) Intravenous gene therapy with PIM-1 via a cardiotropic viral vector halts the progression of diabetic cardiomyopathy through promotion of prosurvival signaling. Circ Res 108 (10):: 1238-51.
32. Katare R, Oikawa A, Cesselli D, Beltrami AP, Avolio E, et al. (2013) Boosting the pentose phosphate pathway restores cardiac progenitor cell availability in diabetes. Cardiovasc Res 97 (1):: 55-65.